Send your comments and tips to email@example.com
Beth Israel Deaconess Medical Ctr.
Boston Medical Center
Brigham and Women's Hospital
Cambridge Health Alliance
Caritas St. Elizabeth's Medical Ctr.
Children's Hospital Boston
Dana-Farber Cancer Institute
Joslin Diabetes Center
Mass. General Hospital
Mass. Health Law
New England Baptist Hospital
Short White Coat
Tufts-New England Medical Center
UMass Memorial Medical Center
University of Massachusetts
VA Medical Centers
A Healthy Blog
Running A Hospital
Nature Network Boston
SciBos - Corie Lok's blog
Nurse at small
Dr. Gwenn Is In
Healthy Children blog
Other Globe Blogs
Elizabeth Cooney is a health reporter for the Worcester Telegram & Gazette.
Boston Globe Health and Science staff:
Karen Weintraub, Deputy Health and Science Editor, and Gideon Gil, Health and Science Editor.
Short White Coat blogger Ishani Ganguli
Short White Coat blogger Jennifer Srygley
Tuesday, May 22, 2007
Today's Globe: diabetes drug and heart risks, pitching health insurance, stent rivals
Avandia, the world's top-selling oral diabetes drug, significantly increases the risk of heart attacks, a prominent cardiologist said in an article that the New England Journal of Medicine deemed important enough to post on its website yesterday, weeks before the scheduled print publication date. Patients taking Avandia should not abruptly stop the drug, the FDA said. Instead, they should meet with their doctors to discuss their risk of a heart attack and how well their diabetes is controlled, according to Dr. Larry C. Deeb, president of medicine and science for the American Diabetes Association.
Jon Kingsdale, executive director of the Commonwealth Health Insurance Connector Authority, which is overseeing implementation of the state's healthcare revamp, will gather with state political leaders and Red Sox executives today at Fenway Park to unveil a $3 million advertising campaign (above) that is heavily tied to the Red Sox and will be featured on the team's cable television outlet, New England Sports Network.
Medtronic Inc. will report today that its stent for preventing heart attacks didn't cause blood clots in tests, increasing the company's chances of expanding its share of the $5.4 billion-a-year worldwide market. The results, to be presented at a scientific meeting in Barcelona, suggest that experimental devices may be safer than those sold by Johnson & Johnson and Boston Scientific Corp.